Monitor enrollment progress and data readouts from the Phase 3 RESTORE study (NCT07799532). Breakthrough Therapy designation increases the likelihood of expedited FDA review but does not guarantee approval; the Phase 3 results will be the key catalyst.
Drug in focus
NGEN drug pipeline →NVG-291
● Neutral Named in this press release- Impact
- Phase
- Phase 3 (registrational)
- Time to market
- If Phase 3 RESTORE succeeds, a potential FDA submission could occur in 2028-2029, assuming enrollment completes and the 16-week treatment period yields positive results. Breakthrough Therapy designation may accelerate FDA review.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 3 RESTORE topline data readout, likely in late 2027 or 2028 given enrollment just began in October 2026. Positive data would validate NVG-291 as a first-in-class neuroreparative therapy for a large unmet need with no approved pharmacologic alternatives; negative data would be devastating for this single-asset company. Interim enrollment updates or any early efficacy signals could also move the stock.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $1.63entry
- T+1 · 4d ago +15.34%α +15.70% · $1.88
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NervGen Pharma announced that the FDA granted Breakthrough Therapy designation to NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury, based on Phase 1b/2a CONNECT SCI data showing functional hand use improvements. The designation may expedite development and regulatory review, but does not guarantee approval.
Key Facts
- FDA granted Breakthrough Therapy designation for NVG-291 in chronic traumatic cervical motor-incomplete SCI
- Designation based on safety and efficacy data from Phase 1b/2a CONNECT SCI study
- Phase 3 RESTORE registrational study is enrolling, targeting ~150 participants in US and Canada
- NVG-291 is a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway
- No serious adverse events or treatment discontinuations in the Phase 1b/2a study
- Approximately 312,000 people in the US live with traumatic SCI; no FDA-approved pharmacologic therapies for chronic SCI
Financial Impact
Breakthrough Therapy designation is a regulatory milestone that could accelerate path to approval for a first-in-class therapy addressing a large unmet need; no financial terms disclosed
Risk Factors
- Breakthrough Therapy designation does not guarantee regulatory approval
- Phase 3 results may not replicate Phase 1b/2a findings
- Small market cap ($150M) implies high event sensitivity
- No currently approved pharmacologic therapies for chronic SCI; commercial adoption uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401443 |
Track record
19 reports on NGEN
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +51.65% at T+60 after the May 18, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry $1.87 Now $1.82 −2.67% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 6/10 Viewing Entry $1.63 Now $1.82 +11.66% settles Nov 19
- Sep 25, 20267w ago 6-K Bearish 7/10 Entry $1.88 to $1.81 Now $1.82 +3.19% ▲ +3.72% +4.93% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $1.88 to $1.81 Now $1.82 −3.19% ▼ −3.72% −4.93% vs SPY
- Sep 24, 20267w ago 6-K Neutral 3/10 Entry $2.02 to $1.76 Now $1.82 −9.90% ▼ −12.87% −12.46% vs SPY
- Aug 13, 202613w ago 6-K Neutral 5/10 Entry $1.76 to $1.76 Now $1.82 +3.41% · 0.00% +1.96% vs SPY
- Aug 13, 202613w ago Press Release Neutral 5/10 Entry $1.76 to $1.76 Now $1.82 +3.41% · 0.00% +1.96% vs SPY
- Jul 2, 202619w ago 6-K Bearish 5/10 Entry $2.12 to $1.86 Now $1.82 +14.15% ▲ +12.26% +13.19% vs SPY
- Jun 1, 202624w ago 6-K Bearish 6/10 Entry $2.00 to $1.81 Now $1.82 +9.00% ▲ +9.50% +6.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers